Immunotherapy Gotistobart Nearly Doubles Overall Survival in Previously Treated Squamous Non-Small Cell Lung Cancer

When squamous non-small cell lung cancer stops responding to initial immunotherapy, the outcome is largely determined by the regulatory T cells inside the tumor microenvironment—the biological brakes that prevent the immune system from attacking the cancer. If those brakes cannot be selectively removed, patients are left with standard chemotherapy and a median survival of less than a year. Now, updated clinical trial data presented Monday show that an investigational antibody designed to specifically deplete those regulatory T cells nearly doubles overall survival in this heavily pretreated population, offering a potential lifeline where options have historically been scarce.[1][2]

The drug, gotistobart (also known as BNT316 or ONC-392), is an investigational immunotherapy being jointly developed by BioNTech and OncoC4. During the 2026 World Conference on Lung Cancer in Seoul, researchers presented mature data from the first stage of the global Phase 3 PRESERVE-003 trial. The study specifically enrolled patients whose disease had progressed despite prior treatment with PD-(L)1 inhibitors and platinum-based chemotherapy, a demographic that typically faces a grim prognosis and rapidly deteriorating quality of life as their tumors evade immune detection.[2][4]

The trial results demonstrated a stark divergence in patient outcomes based on their assigned treatment. Patients receiving gotistobart achieved a median overall survival of 18.5 months, compared to exactly 10.0 months for those receiving the standard-of-care chemotherapy docetaxel. This translates to a 44% reduction in the risk of death (hazard ratio 0.56) at the latest data cutoff, confirming earlier preliminary analyses that showed a 54% reduction. For a disease setting where survival is typically measured in mere months, an 8.5-month absolute extension represents an unprecedented leap in efficacy.[1][3]

"Current survival expectations with established therapies remain less than a year, and despite numerous development efforts, chemotherapy has remained the standard of care in this setting for more than a decade," said Dr. Rama Balaraman, a principal investigator in the trial and medical oncologist. She noted that confirming this survival benefit in the trial's next phase could "transform the standard of care" by offering a chemotherapy-free alternative. For patients, this could mean avoiding the systemic toxicity of docetaxel while achieving significantly longer disease control.[2]

The mechanism driving this extended survival hinges on pH sensitivity. First-generation CTLA-4 inhibitors, like ipilimumab, bind to the CTLA-4 receptor and trigger its destruction in cellular lysosomes, which can cause severe immune-related side effects throughout the body. Gotistobart, however, is designed to release the receptor when exposed to the acidic environment inside a cellular vesicle. This allows the CTLA-4 protein to recycle back to the cell surface, preserving its normal immune-calming function in healthy tissue while aggressively depleting regulatory T cells specifically within the highly acidic tumor microenvironment.[5][6]

That targeted biochemical approach appears to translate directly into durable tumor control. Earlier data from the trial showed that 20.0% of patients on gotistobart achieved a confirmed objective response, compared to just 4.8% of patients on docetaxel. More importantly, those responses lasted significantly longer, with a median duration of 11.0 months for the immunotherapy versus 3.8 months for chemotherapy. By preserving the immune system's peripheral brakes, the drug allows patients to stay on therapy long enough to mount a sustained attack against the cancer.[3][6]

The survival gains do come with a challenging safety profile, a known hurdle for the entire CTLA-4 drug class. Severe treatment-related adverse events—most notably colitis and elevated liver enzymes—occurred in roughly 42% to 44% of patients taking gotistobart, leading approximately 15% to discontinue the therapy entirely. However, researchers characterized the safety profile as manageable and consistent with previous studies, noting that the rates of severe toxicity were actually comparable to the 49% rate seen in the docetaxel chemotherapy arm.[1][2]

The pivotal second stage of the PRESERVE-003 trial is currently enrolling patients across 160 global sites to confirm these findings in a larger cohort. For patients currently facing a recurrence, these results offer a tangible reason for hope, though the drug remains investigational and is not yet available outside of clinical trials. Because gotistobart has already received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration, a successful Phase 3 readout could rapidly shift the treatment paradigm for the roughly 25% of lung cancer patients diagnosed with the aggressive squamous subtype.[2][4]